Compare MBLY & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBLY | HALO |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.1B |
| IPO Year | 2022 | 2001 |
| Metric | MBLY | HALO |
|---|---|---|
| Price | $9.83 | $81.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 11 |
| Target Price | $14.13 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 6.2M | 1.7M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.43 | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | ★ $1,894,000,000.00 | $151,862,000.00 |
| Revenue This Year | $4.91 | $28.24 |
| Revenue Next Year | $13.94 | $12.56 |
| P/E Ratio | ★ N/A | $66.21 |
| Revenue Growth | ★ 14.51 | N/A |
| 52 Week Low | $6.47 | $55.64 |
| 52 Week High | $20.18 | $82.22 |
| Indicator | MBLY | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | 75.99 |
| Support Level | $8.43 | $67.12 |
| Resistance Level | $10.54 | $82.22 |
| Average True Range (ATR) | 0.52 | 2.35 |
| MACD | 0.17 | 1.02 |
| Stochastic Oscillator | 82.92 | 97.11 |
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.